Quintiles maintains 'outperform' rating following recent flurry of activity

By Dan Stanton

- Last updated on GMT

Related tags Asia-pacific

A new Asia-Pacific market access service and the acquisition of Japanese CRO Clio Science has helped bolster Quintiles' investment desirability
A new Asia-Pacific market access service and the acquisition of Japanese CRO Clio Science has helped bolster Quintiles' investment desirability
A recent spate of activity - including the acquisition of a Japanese CRO and a secondary equity offering - has boosted Quintiles’ investment appeal, an analyst says.

The world’s largest contract research organisation (CRO) Quintiles has had a busy few weeks:

Last week it announced it has fully acquired Clio Science, a full-service CRO with a staff of 70 based in Tokyo and Osaka. Also this month, Quintiles opened a new bioanalytical lab in the Netherlands​ and, on the financial side,  secured almost $2bn (€1.8bn)​ following the completion of a refinancing programme.

“While none of these events has a major impact on our model, we have updated our estimates to reflect the flurry of activity,”​ William Blair analyst John Kreger said in a note.

“We maintain our Outperform rating on Quintiles given strong bookings and a more attractive valuation of late, and continue to view Quintiles as the most diversified way to invest in late-stage pharma outsourcing.”

Asia-Pacific market access

In its latest announcement, Quintiles is launching a new service for emerging biopharma companies in the Asia-Pacific region, based on its estimation that there are over 1,400 such firms across the region looking for help accessing the regional and global markets.

“We work with all sized companies but smaller emerging biopharma companies have a number of regulatory and access challenges and needs that need to be addressed,”​ Quintiles spokesman Jay Johnson told Outsourcing-Pharma.com.

“Other CROs do offer these services but what we did was take a look at the services that we had across our network in 13 Asia-Pacific countries and decided this new solution set would work best.”

The service includes dedicated local project leadership in the region, offering knowledge of local markets, customs and language, and accelerated patient recruitment due to the firm’s global and Asia-Pacific network.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers